APN 1607

Drug Profile

APN 1607

Alternative Names: 1-(fluoro-18F)-3-((2-((1E,3E)-4-(6-(methylamino)pyridin-3-yl)buta-1,3-dien-1-yl)benzo[d]thiazol-6-yl)oxy)propan-2-ol; 18F-PM-PBB3; APN-1607; PM-PBB3

Latest Information Update: 18 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator APRINOIA Therapeutics
  • Class Diagnostic agents; Imaging agents; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Progressive supranuclear palsy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Alzheimer's disease; Progressive supranuclear palsy

Most Recent Events

  • 16 Jan 2018 APRINOIA Therapeutics plans a phase II/III trial for Alzheimer's disease and Progressive supranuclear palsy (Diagnosis), in second quarter of 2018 (APRINOIA Therapeutics pipeline, January 2018)
  • 31 Dec 2017 Phase-I/II clinical trials in Alzheimer's disease in Japan, USA (Diagnosis) (Parenteral), before December 2017 (APRINOIA Therapeutics pipeline, January 2018)
  • 31 Dec 2017 Phase-I/II clinical trials in Progressive supranuclear palsy in USA, Japan (Diagnosis) (Parenteral), before December 2017 (APRINOIA Therapeutics pipeline, January 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top